Steven D. Barrett


Co-Chair, Technology Transactions and Licensing Practice Group

Barrett, Steven D.

Steve Barrett, co-chair of the Technology Transactions and Licensing Practice Group, advises a variety of life sciences and technology companies regarding the structuring, negotiation and drafting of agreements for a broad range of technology transactions, including technology acquisition, license, strategic alliance and joint venture transactions, and related research, development, supply, marketing, distribution and services agreements. Mr. Barrett regularly represents entrepreneurs, early-stage and established life sciences and technology companies and large commercial enterprises.

Learn more about Mr. Barrett's practice and how he can support your startup on

Honors & Awards

  • Recognized as a leader in life sciences in the 2015 and 2016 editions of Who's Who Legal
  • Recommended in the 2016 and 2017 editions of The Legal 500 United States for his work in M&A/Corporate and Commercial as well as Media, Technology and Telecoms: Outsourcing and Transactions
  • Recognized for his practice and named a "Life Sciences Star" in the 2012-2017 editions of LMG Life Sciences and named to its 2017 awards shortlist for Finance & Transactional Attorney of the Year: Licensing & Collaboration. He was also awarded one of five Finance and Transactional Impact Cases of the Year by LMG for counseling Editas Medicine in its licensing and collaboration with Allergan.
  • Recognized in each edition of the PLC Cross-border Life Sciences Handbook in the USA Commercial and Partnering category since the 2006/07 edition; listed as Leading in this category in the 2009/10 and 2011/12 editions
  • Named "Massachusetts Super Lawyer" in the areas of intellectual property and business/corporate law in the 2014-2016 editions of Boston Magazine
  • Named a "Massachusetts Super Lawyers Rising Star" in intellectual property law in the 2005 and 2006 issues of Boston Magazine

Publications & News


March 20, 2018

WilmerHale Counsels Vividion in Strategic Research Collaboration with Celgene

Vividion Therapeutics, a biotechnology company using novel proteomics and chemistry platforms, has announced that it entered into a strategic research collaboration with Celgene Corporation and will receive $101 million in upfront and equity consideration.

February 28, 2018

WilmerHale Represents Generation Bio in $100M Series B Financing

Generation Bio, a company developing the first genetic medicines that can be titrated to effect and re-dosed for a lifetime of benefit, recently announced the closing of a $100 million Series B financing.

January 26, 2018

WilmerHale Represents Spark Therapeutics in Licensing and Supply Agreement With Novartis

Spark Therapeutics, a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, announced it has entered into a licensing agreement with Novartis Pharmaceuticals to develop and commercialize investigational voretigene neparvovec outside the United States.

January 3, 2018

WilmerHale Represents Viamet Pharmaceuticals in Acquisition by NovaQuest Capital Management

Viamet Pharmaceuticals (NC), Inc. today announced that it has entered into an agreement with NovaQuest Capital Management, L.L.C. for the acquisition of Viamet Pharmaceuticals, including the company's product candidate, VT-1161.

December 5, 2017

Astellas Acquires Mitobridge Under Existing Collaboration

Astellas Pharma Inc. and Mitobridge, Inc. announced that Astellas has exercised its exclusive option right to acquire Mitobridge under the amended terms of the October 2013 partnership agreement.

November 7, 2017

LMG Life Sciences 2017 Honors WilmerHale With Top Rankings

LMG Life Sciences has recognized WilmerHale among the nation's leading life sciences law firms in its 2017 rankings, citing the firm's Life Sciences Practice as “renowned for its range and multidisciplinary teams that counsel clients in technology, pharmaceutical and medical device companies as well as investment banks and venture capitalists.”

October 26, 2017

WilmerHale Reps MacroGenics in Global Collaboration and Licensing Agreement With Incyte

MacroGenics, Inc. and Incyte Corporation announced that they have entered into an exclusive global collaboration and license agreement for MacroGenics' MGA012, an investigational monoclonal antibody that inhibits programmed cell death protein 1 (PD-1).

September 19, 2017

LMG Life Sciences Names WilmerHale Life Cycle Firm of the Year and Lisa Pirozzolo General Patent Litigator of the Year

Lawyers from across the United States and Canada gathered on September 13 at the Essex House in New York to celebrate the annual LMG Life Sciences Awards, recognizing the 2017 top firms and legal professionals in the life science industry.

August 14, 2017

WilmerHale Counsels Investors Abingworth Bioventures and Atlas Venture in IFM Therapeutics Acquisition by Bristol-Myers Squibb

Bristol-Myers Squibb Company and IFM Therapeutics announced that the companies have signed a definitive agreement under which Bristol-Myers Squibb will acquire all of the outstanding capital stock of IFM Therapeutics, a venture-backed biotech company focused on developing therapies that modulate novel targets in the innate immune system to treat cancer, autoimmunity and inflammatory disorders.

July 20, 2017

LMG Life Sciences Recognizes WilmerHale in 13 Categories on 2017 Award Shortlist

In its annual recognition of the top law firms, lawyers and in-house counsel in the life sciences industry, LMG Life Sciences named WilmerHale to its 2017 award shortlist in 13 categories.

Recent Highlights

Mr. Barrett has recently represented:

  • Adimab in its antibody platform licensing agreements with GSK (2013), Biogen Idec (2013), Novo Nordisk (2013) and Merck (2015)
  • Agios Pharmaceuticals in its licensing agreement for metabolic immuno-oncology inhibitors with Aurigene Discovery Technologies Limited (2017)
  • Agios Pharmaceuticals in its metabolic immuno-oncology collaboration with Celgene (2016)
  • Alnylam in its Asian territory TTR-mediated amyloidosis RNAi collaboration with Genzyme (2012)
  • Alnylam in its prior collaborations with Medtronic (2007), Takeda (2008), Cubist (2009) and GSK (2011)
  • Concert Pharmaceuticals in its multi-program deuterium-modified drug collaboration with Celgene (2013)
  • Concert Pharmaceuticals in its prior collaborations with GSK (2009), Avanir Pharmaceuticals (2012) and Jazz Pharmaceuticals (2013)
  • Dendreon in its $125 million sale of its royalty interest in VICTRELIS™ (boceprevir) to CPPIB Credit Investments (2011)
  • Editas Medicine in its strategic alliance and option agreement with Allergan (2017)
  • Editas Medicine in its licensing of CRISPR technologies from the Broad Institute, MIT, Harvard and other academic institutions (2016)
  • Epizyme in its combination clinical trial collaboration with Genentech (2016)
  • Epizyme in its restructuring of its collaboration with Celgene (2015)
  • Epizyme in its reacquisition of EZH2 inhibitor oncology program rights from Eisai (2015)
  • Epizyme in its prior collaborations with GSK (2011), Eisai (2011), Celgene (2012), Roche Molecular Systems (2012) and Abbott Molecular (2013)
  • Idera Pharmaceuticals in its companion diagnostic development agreement with Abbott Molecular (2014)
  • Lexicon in its worldwide collaboration and licensing agreement for sotagliflozin with Sanofi (2015)
  • Lexicon in its ex-US and Japan licensing agreement for telotristat etiprate with Ipsen (2014)
  • MacroGenics in its anti-PD-1 monoclonal antibody collaboration with Incyte (2017)
  • Merrimack Pharmaceuticals in its >$970 million ex-US license and collaboration agreement with Baxter (2014)
  • Merrimack in its prior collaborations with Sanofi-Aventis (2009), PharmaEngine (2011) and Actavis (2013)
  • Mitobridge in its $730 million mitochondria-related disease collaboration with Astellas (2013)
  • Nosocomial Vaccine Corporation in its collaboration with Astellas, Affinivax and University of Maryland (2015)
  • Ophthotech in its >$1 billion ex-US licensing and commercialization agreement for FOVISTA™ with Novartis (2014)
  • Ophthotech in its $175 million royalty financing arrangement with Novo A/S (2013)
  • Potenza Therapeutics in its immuno-oncology collaboration with Astellas (2015)
  • Spark Therapeutics in its ex-US licensing and commercialization agreement for LUXTURNA™ with Novartis (2018)
  • Spark Therapeutics in its synthetic vaccine particles licensing transaction with Selecta Biosciences (2016)
  • Spark Therapeutics in its hemophilia B gene therapy collaboration with Pfizer (2014)
  • Spark Therapeutics in its prior licensing agreements with Genable Technologies (2014) and Children's Hospital of Philadelphia (2013)
  • Summit Therapeutics in its Latin America license and commercialization agreement for its ridinilazole antibiotic for the treatment of Clostridium difficile infection with Eurofarma Laboratórios (2017)
  • Summit Therapeutics in its Duchenne muscular dystrophy collaboration with Sarepta Therapeutics (2016)
  • Vertex Pharmaceuticals in its collaboration and licensing agreement to develop ENaC inhibitors for cystic fibrosis and other pulmonary diseases with Parion Sciences (2015)
  • Vividion Therapeutics in its small molecule ubiquitin proteome collaboration with Celgene (2018)

Community Involvement

Mr. Barrett serves on the board of directors of The Political Asylum/Immigration Representation (PAIR) Project. Mr. Barrett has also successfully represented, on a pro bono basis, a number of persons who have fled persecution in other countries and sought political asylum in the United States.

Mr. Barrett served on active duty as a US naval officer from 1989 to 1992. His assignments included division officer tours in USS Hoel (DGG-13) and USS Waddell (DDG-24), and he qualified as a surface warfare officer and was awarded the Navy Achievement Medal.


Skip Navigation Links.


JD, cum laude, University of Michigan Law School, 1996

MBA, with High Distinction, University of Michigan, 1996

SB, Mechanical Engineering, Massachusetts Institute of Technology, 1989

Bar Admissions



United States Patent and Trademark Office

Skip Navigation Links.